A comparison of the efficacy of Symbicort [budesonide/formoterol] single inhaler therapy (Symbicort Turbuhaler 160/4.5 mg 1 inhalation b.i.d. plus as-needed) and conventional best standard treatment for the treatment of persistent asthma in adolescents and adults. A randomized, open, parallel-group, multicentre 26-weeks study

Trial Profile

A comparison of the efficacy of Symbicort [budesonide/formoterol] single inhaler therapy (Symbicort Turbuhaler 160/4.5 mg 1 inhalation b.i.d. plus as-needed) and conventional best standard treatment for the treatment of persistent asthma in adolescents and adults. A randomized, open, parallel-group, multicentre 26-weeks study

Completed
Phase of Trial: Phase IV

Latest Information Update: 02 Jun 2011

At a glance

  • Drugs Antiasthmatics; Budesonide/formoterol
  • Indications Asthma
  • Focus Therapeutic Use
  • Most Recent Events

    • 21 Jan 2011 Trial phase changed from III to IV as reported by ClinicalTrials.gov.
    • 07 Oct 2008 Results were reported at the Annual Congress of the European Respiratory Society.
    • 07 Oct 2008 Primary endpoint 'Time to exacerbation of symptoms' has been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top